SCHEMBL3000163

SCHEMBL3000163

CCc1ccc(Cc2csc(N3CCN(S(=O)(=O)c4ccc(C)cc4)CC3)n2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.47
ALDH1A1 P00352 2/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
THRB P10828 1/20 0.47
TSHR P16473 1/20 0.44
HDAC3 O15379 1/20 0.44
HDAC4 P56524 1/20 0.44
HDAC1 Q13547 1/20 0.44
HDAC7 Q8WUI4 1/20 0.44
HDAC2 Q92769 1/20 0.44
HDAC10 Q969S8 1/20 0.44
HDAC11 Q96DB2 1/20 0.44
HDAC8 Q9BY41 1/20 0.44
HDAC6 Q9UBN7 1/20 0.44
HDAC9 Q9UKV0 1/20 0.44
HDAC5 Q9UQL6 1/20 0.44
USP2 O75604 1/20 0.44
POLB P06746 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3012775 0.96 MEN1 (0.51) SMN1; SMN2ALDH1A1L3MBTL1MEN1KMT2A
SCHEMBL3015670 0.92 SMN1; SMN2 (0.46) SMN1; SMN2ALDH1A1L3MBTL1MEN1KMT2A
SCHEMBL2998702 0.91 SMN1; SMN2 (0.47) SMN1; SMN2ALDH1A1L3MBTL1MEN1KMT2A
SCHEMBL3006852 0.91 ALDH1A1 (0.48) SMN1; SMN2ALDH1A1L3MBTL1MEN1KMT2A
SCHEMBL3015956 0.91 SMN1; SMN2 (0.47) SMN1; SMN2ALDH1A1L3MBTL1MEN1KMT2A
SCHEMBL3010733 0.91 ALDH1A1 (0.48) SMN1; SMN2ALDH1A1L3MBTL1MEN1KMT2A
SCHEMBL3018625 0.91 ALDH1A1 (0.60) SMN1; SMN2ALDH1A1L3MBTL1MEN1KMT2A
SCHEMBL3023130 0.91 ALDH1A1 (0.60) SMN1; SMN2ALDH1A1L3MBTL1MEN1KMT2A
SCHEMBL3011282 0.91 SMN1; SMN2 (0.47) SMN1; SMN2ALDH1A1L3MBTL1MEN1KMT2A
SCHEMBL3008181 0.91 SMN1; SMN2 (0.47) SMN1; SMN2ALDH1A1L3MBTL1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA SMN1; SMN2 1/4885ALDH1A1 3510/4885L3MBTL1 1847/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.